Cash and cash equivalents

Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 6, 2021

Key findings include:\nFLT3-targeting TriTACs\xc2\xa0are T cell engagers with a potential role in the treatment of acute myeloid leukemia.

Key Points: 
  • Key findings include:\nFLT3-targeting TriTACs\xc2\xa0are T cell engagers with a potential role in the treatment of acute myeloid leukemia.
  • HPN217 targets B-cell maturation antigen (BCMA).\nHarpoon ended the first quarter of 2021 with $239.4 million in cash, cash equivalents, and marketable securities compared to $150.0 million as of December 31, 2020.
  • These forward-looking statements are based on Harpoon Therapeutics\xe2\x80\x99 expectations and assumptions as of the date of this press release.
  • Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.\n'

Healthcare Trust of America, Inc. Reports Record First Quarter 2021 Earnings And Tightens 2021 Earnings Guidance

Retrieved on: 
Thursday, May 6, 2021

b"The updated 2021 outlook guidance includes the following additional assumptions:\n$300 - $600 million of investments at an average 5.5% to 6.0% yield;\n$65 - $100 million of dispositions at a 5.0% to 7.0% yield;\ngeneral and administrative costs of $43 - $46 million;\naverage fully diluted shares of between 226 and 229 million fully diluted shares of common stock outstanding, with proceeds from equity previously raised on a forward basis being utilized to fund acquisitions as they close; and\ndevelopments being substantially completed as planned.\nThe lower end of the range assumes settlement of forward equity agreements without deployment of cash proceeds for investments.\nHTA expects leverage, measured as (i) debt less cash and cash equivalents to total capitalization, and (ii) measured as debt less cash and cash equivalents to Adjusted EBITDAre to range between 5.5x and 6.0x throughout the year.\nHTA's 2021 guidance is based on a number of various assumptions that are subject to change and many of which are outside the control of the Company.Additionally, HTA's guidance does not contemplate impacts from gains or losses from dispositions, potential impairments, or debt extinguishment costs, if any.If actual results vary from these assumptions, HTA's expectations may change.There can be no assurance that HTA will achieve these results.\nAbout Healthcare Trust of America, Inc.\nHealthcare Trust of America, Inc. (NYSE: HTA) is the largest dedicated owner and operator of MOBs in the United States, with assets comprising approximately 25.6 million square feet of GLA, and with $7.5 billion invested primarily in MOBs.HTA provides real estate infrastructure for the integrated delivery of healthcare services in highly-desirable locations.Investments are targeted to build critical mass in 20 to 25 leading gateway markets that generally have leading university and medical institutions, which generally translates to superior demographics, high-quality graduates, intellectual talent and job growth.The strategic markets HTA invests in support a strong, long-term demand for quality medical office space.HTA utilizes an integrated asset management platform consisting of on-site leasing, property management, engineering and building services, and development capabilities to create complete, state of the art facilities in each market.We believe this drives efficiencies, strong tenant and health system relationships, and strategic partnerships that result in high levels of tenant retention, rental growth and long-term value creation.

Key Points: 
  • b"The updated 2021 outlook guidance includes the following additional assumptions:\n$300 - $600 million of investments at an average 5.5% to 6.0% yield;\n$65 - $100 million of dispositions at a 5.0% to 7.0% yield;\ngeneral and administrative costs of $43 - $46 million;\naverage fully diluted shares of between 226 and 229 million fully diluted shares of common stock outstanding, with proceeds from equity previously raised on a forward basis being utilized to fund acquisitions as they close; and\ndevelopments being substantially completed as planned.\nThe lower end of the range assumes settlement of forward equity agreements without deployment of cash proceeds for investments.\nHTA expects leverage, measured as (i) debt less cash and cash equivalents to total capitalization, and (ii) measured as debt less cash and cash equivalents to Adjusted EBITDAre to range between 5.5x and 6.0x throughout the year.\nHTA's 2021 guidance is based on a number of various assumptions that are subject to change and many of which are outside the control of the Company.Additionally, HTA's guidance does not contemplate impacts from gains or losses from dispositions, potential impairments, or debt extinguishment costs, if any.If actual results vary from these assumptions, HTA's expectations may change.There can be no assurance that HTA will achieve these results.\nAbout Healthcare Trust of America, Inc.\nHealthcare Trust of America, Inc. (NYSE: HTA) is the largest dedicated owner and operator of MOBs in the United States, with assets comprising approximately 25.6 million square feet of GLA, and with $7.5 billion invested primarily in MOBs.HTA provides real estate infrastructure for the integrated delivery of healthcare services in highly-desirable locations.Investments are targeted to build critical mass in 20 to 25 leading gateway markets that generally have leading university and medical institutions, which generally translates to superior demographics, high-quality graduates, intellectual talent and job growth.The strategic markets HTA invests in support a strong, long-term demand for quality medical office space.HTA utilizes an integrated asset management platform consisting of on-site leasing, property management, engineering and building services, and development capabilities to create complete, state of the art facilities in each market.We believe this drives efficiencies, strong tenant and health system relationships, and strategic partnerships that result in high levels of tenant retention, rental growth and long-term value creation.
  • Headquartered in Scottsdale, Arizona, HTA has developed a national brand with dedicated relationships at the local level.\nFounded in 2006 and listed on the New York Stock Exchange in 2012, HTA has produced attractive returns for its stockholders that have outperformed the US REIT index.More information about HTA can be found on the Company's Website ( www.htareit.com ), Facebook, LinkedIn and Twitter.\nThis press release contains certain forward-looking statements with respect to HTA.
  • Forward-looking statements are statements that are not descriptions of historical facts and include statements regarding management's intentions, beliefs, expectations, plans or predictions of the future, within the meaning of Section27A of the Securities Act of 1933, as amended, and Section21E of the Securities Exchange Act of 1934, as amended.
  • Because such statements include risks, uncertainties and contingencies, actual results may differ materially and in adverse ways from those expressed or implied by such forward-looking statements.These risks, uncertainties and contingencies include, without limitation, the following: changes in economic conditions generally and the real estate market specifically; legislative and regulatory changes, including changes to laws governing the taxation of REITs and changes to laws governing the healthcare industry; the availability of capital; changes in interest rates; competition in the real estate industry; the supply and demand for operating properties in our proposed market areas; changes in accounting principles generally accepted in the United States of America; policies and guidelines applicable to REITs; the availability of properties to acquire; the availability of financing; pandemics and other health concerns, and the measures intended to prevent their spread, including the currently ongoing COVID-19 pandemic; and the potential material adverse effect these matters may have on our business, results of operations, cash flows and financial condition.Additional information concerning us and our business, including additional factors that could materially and adversely affect our financial results, include, without limitation, the risks described under Part I, Item1A - Risk Factors, in our 2021 Annual Report on Form 10-K and in our filings with the SEC.\nHTA will host a conference call and webcast on Friday, May 7, 2021 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time) to review its financial performance and operating results for the three months ended March 31, 2021.\nConference Call and Webcast Details:\nAvailable May 7, 2021 (one hour after the end of the conference call) to June 7, 2021 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time)\n"

Adaptimmune Reports First Quarter Financial Results and Business Update

Retrieved on: 
Thursday, May 6, 2021

We have seen good enrollment in the SURPASS and ADP-A2AFP trials and will present data later this year,\xe2\x80\x9d said Adrian Rawcliffe, Adaptimmune\xe2\x80\x99s Chief Executive Officer.

Key Points: 
  • We have seen good enrollment in the SURPASS and ADP-A2AFP trials and will present data later this year,\xe2\x80\x9d said Adrian Rawcliffe, Adaptimmune\xe2\x80\x99s Chief Executive Officer.
  • \xe2\x80\x9cWe continue to deliver against our ambitions laid out in our 2-2-5-2 strategic plan to bring products forward for clinical development and launch.
  • At ASGCT next week, we will present preclinical data from our first HiT product targeting mesothelin.
  • The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in millions):\n'

Quarterhill Announces First Quarter Fiscal 2021 Financial Results

Retrieved on: 
Thursday, May 6, 2021

b'TORONTO, May 6, 2021 /PRNewswire/ -Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), announces its financial results for the three-month period ended March31, 2021.

Key Points: 
  • b'TORONTO, May 6, 2021 /PRNewswire/ -Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), announces its financial results for the three-month period ended March31, 2021.
  • All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.\nConsolidated Adjusted EBITDA1 was ($0.4) million.
  • Cash and cash equivalents and short-term investments was $132.0 million at March31, 2021, compared to $141.3 million at December 31, 2020.
  • Working capital at March31, 2021, was $150.3 million compared to $159.7 million at December 31, 2020.\nQuarterhill will host a conference call to discuss its financial results today at 10:00 AM Eastern Time.

GBT Reports First Quarter 2021 Financial Results

Retrieved on: 
Wednesday, May 5, 2021

Despite the headwinds we expected from the COVID-19 pandemic during the quarter, we continue to deliver new prescriptions, and the net number of patients on Oxbryta has increased each quarter since launch.

Key Points: 
  • Despite the headwinds we expected from the COVID-19 pandemic during the quarter, we continue to deliver new prescriptions, and the net number of patients on Oxbryta has increased each quarter since launch.
  • Basic and diluted net loss per share for the three months ended\xc2\xa0March 31, 2021, was\xc2\xa0$1.21\xc2\xa0compared with\xc2\xa0$1.20\xc2\xa0for the same period in 2020.
  • GBT anticipates a sequential increase in operating expenses in the second quarter of 2021 as the company continues to ramp up these efforts.\nCash, cash equivalents, and marketable securities totaled\xc2\xa0$482.0 million\xc2\xa0at\xc2\xa0March 31, 2021, compared with\xc2\xa0$560.9 million\xc2\xa0at\xc2\xa0December 31, 2020.\nGBT will host a conference call today, Wednesday, May 5, 2021, at 4:30 p.m.
  • ET to provide a general business update and discuss the financial results for the first quarter 2021.

USD Partners LP Announces First Quarter 2021 Results

Retrieved on: 
Wednesday, May 5, 2021

b"USD Partners LP (NYSE: USDP) (the \xe2\x80\x9cPartnership\xe2\x80\x9d) announced today its operating and financial results for the three months ended March 31, 2021.

Key Points: 
  • b"USD Partners LP (NYSE: USDP) (the \xe2\x80\x9cPartnership\xe2\x80\x9d) announced today its operating and financial results for the three months ended March 31, 2021.
  • As of the end of the first quarter of 2021, the Partnership had borrowings of $189 million outstanding under the Revolving Credit Facility.
  • As such, the Partnership\xe2\x80\x99s available borrowings under the senior secured credit facility, including unrestricted cash and cash equivalents, was approximately $75 million as of March 31, 2021.
  • Therefore, actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements.

GoDaddy Reports First Quarter 2021 Earnings Results

Retrieved on: 
Wednesday, May 5, 2021

Share repurchases will be funded by available cash and cash equivalents.\nFor the second quarter ending June 30, 2021, GoDaddy expects revenue of approximately $920 million, or approximately 14% year over year growth.

Key Points: 
  • Share repurchases will be funded by available cash and cash equivalents.\nFor the second quarter ending June 30, 2021, GoDaddy expects revenue of approximately $920 million, or approximately 14% year over year growth.
  • Our reported results provide reconciliations of non-GAAP financial measures to their nearest GAAP equivalents.\nGoDaddy will host a conference call and webcast to discuss first quarter 2021 results at 5:00 p.m. Eastern Time on May5, 2021.
  • A transcript of pre-recorded remarks will be available on the Investor Relations website at the time of the earnings call.
  • Additional information will also be set forth in other filings that GoDaddy makes with the SEC from time to time.

ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021

Retrieved on: 
Tuesday, May 4, 2021

b'Net loss for the first quarter of 2021 was \xe2\x82\xac11.9 million, down \xe2\x82\xac5.6 million (-32%) year-over-year, with a \xe2\x82\xac5.8 million decrease (-31%) in operating loss and a \xe2\x82\xac0.2 million decrease in financial income.

Key Points: 
  • b'Net loss for the first quarter of 2021 was \xe2\x82\xac11.9 million, down \xe2\x82\xac5.6 million (-32%) year-over-year, with a \xe2\x82\xac5.8 million decrease (-31%) in operating loss and a \xe2\x82\xac0.2 million decrease in financial income.
  • The \xe2\x82\xac0.2 million decrease in financial result was mostly related to the IFRS accounting of the convertible notes.\nAs of March 31, 2021, ERYTECH had cash and cash equivalents totaling \xe2\x82\xac37.4 million (approximately $43.9 million), compared with \xe2\x82\xac44.4 million on December 31, 2020.
  • Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer.
  • ERYTECH is part of the CAC\xc2\xa0Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.\n'

TTEC Announces Record First Quarter 2021 Financial Results

Retrieved on: 
Tuesday, May 4, 2021

b'DENVER, May 4, 2021 /PRNewswire/ --TTEC Holdings, Inc. (NASDAQ: TTEC), one of the largest, global CX(customer experience) technology and services innovators for end-to-end digital CX solutions, announced today financial results for the first quarter ended March 31, 2021.\n"Our broad-based financial momentum is accelerating and for the fourth consecutive quarter we have delivered record financial results," commented Ken Tuchman, chairman and chief executive officer of TTEC.

Key Points: 
  • b'DENVER, May 4, 2021 /PRNewswire/ --TTEC Holdings, Inc. (NASDAQ: TTEC), one of the largest, global CX(customer experience) technology and services innovators for end-to-end digital CX solutions, announced today financial results for the first quarter ended March 31, 2021.\n"Our broad-based financial momentum is accelerating and for the fourth consecutive quarter we have delivered record financial results," commented Ken Tuchman, chairman and chief executive officer of TTEC.
  • First quarter bookings mix was diversified across segments, verticals, and geographies.\nCash flow from operations in the first quarter 2021 was $69.8million compared to $62.2million for the first quarter 2020.\nCapital expenditures in the first quarter 2021 were $11.6 million compared to $16.8million for the first quarter 2020.\nAs of March 31, 2021, TTEC had cash and cash equivalents of $144.2 million and debt of $348.7million, resulting in a net debt position of $204.5 million.
  • In addition to cash flow from operations, the credit facility provides TTEC with sufficient financial capacity and flexibility to support working capital as well as growth-oriented investments, strategic acquisitions, and discretionary capital distributions.
  • Financial highlights for the two segments are provided below.\nFirst quarter 2021 GAAP revenue for TTEC Digital decreased 18.0 percent to $63.6 million from $77.6 million for the year ago period.

Jounce Therapeutics Reports First Quarter 2021 Financial Results

Retrieved on: 
Tuesday, May 4, 2021

The poster will include the study design and the rationale for indications chosen for the expansion cohorts.

Key Points: 
  • The poster will include the study design and the rationale for indications chosen for the expansion cohorts.
  • The broad discovery pipeline includes multiple programs targeting diverse immune cell types and PD-(L)1 inhibitor resistance mechanisms.\nFirst Quarter 2021 Financial Results:\nCash position: As of March\xc2\xa031, 2021, cash, cash equivalents and investments increased to $271.3 million, compared to $213.2 million as of December\xc2\xa031, 2020.
  • Jounce did not recognize any license or collaboration revenue in the first quarter of 2020.\nResearch and development expenses: Research and development expenses were $20.5 million for the first quarter of 2021, compared to $19.6 million for the same period in 2020.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.